Saturday, October 3, 2026

Nikkei 225 Slides By 6% In The Last 21 Sessions

ViaNews Editorial Team

October 4, 2023

Nikkei 225 Slides By 6% In The Last 21 Sessions

(VIANEWS) - Nikkei 225 (N225) has been up by 6.87% for the last 21 sessions. At 21:08 EST on Tuesday, 3 October, Nikkei 225 (N225) is $30,677.00.

About Nikkei 225's yearly highs and lows, it's 19.54% up from its 52-week low and 9.17% down from its 52-week high.

Volatility

Nikkei 225's last week, last month's, and last quarter's current intraday variation average was a negative 0.90%, a negative 0.27%, and a positive 0.80%, respectively.

Nikkei 225's highest amplitude of average volatility was 0.90% (last week), 0.81% (last month), and 0.80% (last quarter), respectively.

Index Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Nikkei 225's is considered to be overbought (>=80).

News about

  • According to DailyForex on Monday, 2 October, "The NASDAQ 100 has seen quite a bit of volatility during the month of September, but it looks like we are trying to turn around at the very end of the month and save what looks like a larger "bullish flag. ", "After all, as long as the interest rates continue to show signs of strength, does make people a little bit hesitant to jump in and start buying riskier technology stocks, which of course makes up a majority of the NASDAQ 100. "

More news about Nikkei 225 (N225).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI-Driven Drug Development Meets Biotech Deal-Making and Regulatory Catalysts
AI-designed therapeutics (Insilico's rentosertib showing biological-age reductions) are moving into the clinical mainstream. Large-cap biotech is simultaneously reallocating capital through M&A (Lilly–Merida, $2.9B) and government funding (BARDA–Basilea), while trial failures (ziltivekimab, a 9.4% Novo Nordisk share drop) and upcoming FDA catalysts (the ivonescimab PDUFA on 2026-11-14) drive volatility. The wider AI regulatory and legal climate (Tesla Cybercab probe, xAI's Minnesota loss, OpenAI suits) is tightening, though QAIAx's micro-cap trial claims are speculative and weakly connected.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Apple Inc.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,327 source documents archived
Query this data → isubstrate.com